Cheaper chemo on the horizon? new trial tests generic paclitaxel for breast cancer
NCT ID NCT06765590
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether a generic version of the chemotherapy drug paclitaxel albumin-bound works the same as the brand-name version in people with breast cancer. The trial involves 24 participants who will receive both versions at different times to compare how the drug behaves in their bodies. The goal is to see if the generic can be a safe and effective alternative, potentially making treatment more affordable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
paclitaxel albumin-bound (a chemotherapy drug)
What this could lead to
If successful, this could show that a generic version of this chemotherapy is as effective as the brand-name drug, potentially lowering treatment costs for breast cancer patients.
What could go wrong
This is a small, early-stage bioequivalence study, not designed to prove the drug works better or cures cancer. It only checks if the generic matches the reference drug in the body, not long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated hospital of Hennan University of Science & Technology
RECRUITINGLuoyang, Henan, 471003, China
Contact Email: •••••@•••••